Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)

NCT05969496 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05969496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2023
Completion date
November 30, 2029
Enrollment
17 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

inferior vena cava thrombosis, kidney cancer, renal cancer, renal cell carcinoma